CTOs on the Move

Rainier Therapeutics

www.rainierrx.com

 
Rainier is a uniquely diverse manufacturing company, producing a variety of display, shelter, fabric and shading products. Our mission is to create the highest quality available in everything we create--using the best technology and materials. Rainier consistently meets demanding requirements--and we`re at our best creating new solutions.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.rainierrx.com
  • 1040 Davis Street #202
    San Leandro, CA USA 94577
  • Phone: 925.413.6140

Executives

Name Title Contact Details

Similar Companies

Higher Dimension Research

Higher Dimension Research is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZB RX Medical

ZB RX Medical offers surgical teams nearly 50 marketing representatives and sales personnel well-versed in the challenges faced in orthopedic healthcare today.

Remedi

Remedi SeniorCare is a United States-based institutional pharmacy business, serving a growing number of facilities extending from the Mid-Atlantic to the Midwest.

EyeMarker Systems

EyeMarker Systems is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.